Sustained Virologic Response and Clinical Outcomes in Patients with Chronic Hepatitis C and Advanced Fibrosis

By B. Veldt, E. Heathcote, H. Wedemeyer, J. Reichen, W. Hofmann, S. Zeuzem, Michael P. Manns, B. Hansen, S. Schalm, H. Janssen. Annals of Internal Medicine, 2007

752 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/ac7ef1c11d0a26266f9ac564517ca3b71ef63e91

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. M. Charlton

Citations in the corpus

• Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. (2015, positive): “9 19 (73) 25 (100) 20 (77) 17 (65) 4 (80) 4 (100) 3 (75) 2 (100) 7 (27) 1 (4) 3 (12) 5 (19) 2 (40) 1 (25) 0 0 22 (85) 24 (96) 22 (85) 22 (85) 4 (80) 4 (100) 4 (100) 1 (50)”
• Mechanisms of hepatic fibrogenesis. (2008, neutral): “However, several new areas of rapid progress in the past 5–10 years also have taken root, including: (1) identification of different fibrogenic populations apart from resident stellate cells, for example, portal fibroblasts, fibrocytes, and bone-marrow– derived cells, as well as cells derived from e”
• Hepatitis C Guidance 2019 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection (2019, background): “ Noninvasive tests to assess liver Disease Severity Liver-directed physical exam (normal in most patients) Routine blood tests (e.g., ALT, AST, albumin, bilirubin, INR, and CBC with platelet count) Serum fibrosis marker panels Transient elastography Liver imaging (e.g., ultrasound or computed tomogr”